Clinical Scorecard: Early DCE and DSC Perfusion MRI Parameters as Predictors of Midterm Outcomes in Lung Cancer Brain Metastases Following Stereotactic Radiosurgery

At a Glance

Key Highlights

• Brain metastases from lung carcinoma account for 50% of all brain metastases with poor prognosis despite systemic treatment advances.
• Stereotactic radiosurgery (SRS) is preferred for non-surgical brain metastases to preserve healthy brain tissue and achieve local control.
• Early post-SRS DCE- and DSC-MRI perfusion parameters can predict midterm (6–12 months) tumor response, distinguishing responders from non-responders.

Guideline-Based Recommendations

Diagnosis

• Use baseline and early post-SRS brain MRI including DCE and DSC perfusion imaging within 4–8 weeks after SRS.
• Classify midterm response (6–12 months) using RANO-BM criteria: complete response, partial response, stable disease, or progression.
• Evaluate clinical symptoms (neurological deficits, seizures, cognitive decline) alongside imaging to assess treatment response.

Management

• Employ stereotactic radiosurgery for patients with limited brain metastases (≤5 lesions), controlled extracranial disease, and favorable lesion location.
• Consider patient preference and aim to minimize neurocognitive side effects compared to whole-brain radiotherapy.
• Monitor early perfusion MRI parameters to guide prognosis and potential treatment adjustments.

Monitoring & Follow-up

• Perform follow-up brain MRI with contrast and perfusion imaging at least 6 months post-SRS to assess midterm outcomes.
• Measure lesion volumes at baseline, early post-SRS, and midterm phases using volumetric formula.
• Monitor for radiological progression defined as >20% increase in lesion volume with edema or new solid components.

Risks

• Potential for viable tumor recurrence despite initial local control with SRS.
• Neurocognitive side effects associated with whole-brain radiotherapy, which SRS aims to minimize.
• Contrast administration limitations may impede perfusion imaging quality.

Patient & Prescribing Data

Patients with lung carcinoma brain metastases treated with stereotactic radiosurgery

Early changes in DCE and DSC perfusion MRI parameters post-SRS correlate with midterm tumor control, aiding prognostication and management decisions.

Clinical Best Practices

• Incorporate DCE- and DSC-MRI perfusion imaging into routine early post-SRS assessment to predict midterm outcomes.
• Use RANO-BM criteria combined with clinical evaluation for accurate classification of treatment response.
• Select SRS over whole-brain radiotherapy in eligible patients to preserve neurocognitive function and quality of life.
• Ensure consistent MRI protocols and contrast administration to maintain imaging quality and comparability.

References

• Brain metastases epidemiology and prognosis
• Stereotactic radiosurgery for brain metastases
• RANO-BM criteria for brain metastases response assessment
• Perfusion MRI parameters in tumor angiogenesis
• Use of SRS in small cell lung carcinoma brain metastases